Structures by: Buckingham F.
Total: 7
(3aS*,10aS*,10bS*)-2-methyl-10-tosyl-4,10,10a,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione
C22H20N2O4S
RSC Adv. (2015) 5, 21 16125
a=10.5141(8)Å b=17.9454(11)Å c=11.0976(8)Å
α=90° β=113.865(9)° γ=90°
(3aS*,5S*,10bS*)-5-((S*)-hydroxy(perfluorophenyl)methyl)-N,N-dimethyl-1,3-dioxo-1,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide
C24H20F5N3O5S
RSC Adv. (2015) 5, 21 16125
a=7.9070(4)Å b=14.2862(7)Å c=20.6839(10)Å
α=90° β=101.016(5)° γ=90°
Ethyl 3-((3aS*,4R*,10aS*,10bS*)-1,3-dioxo-10-tosyl-1,2,3,3a,4,10,10a,10b-octahydropyrrolo[3,4-a]carbazol-4-yl)propanoate
C26H26N2O6S
RSC Adv. (2015) 5, 21 16125
a=16.0840(2)Å b=8.84163(10)Å c=18.0999(2)Å
α=90° β=106.2054(14)° γ=90°
6-(3,5-dioxo-4-phenyl-1,2,4-triazolidin-1-yl)-2-phenyl-11-tosyl-5,6-dihydro-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H,11H)-dione
C33H25N7O6S
RSC Adv. (2015) 5, 21 16125
a=13.1236(3)Å b=20.8432(5)Å c=12.0391(2)Å
α=90° β=100.991(2)° γ=90°
2-phenyl-11-tosyl-11,11a-dihydro-1H,5H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-1,3(2H)-dione
C25H20N4O4S,0.5(CH2Cl2)
RSC Adv. (2015) 5, 21 16125
a=6.2586(2)Å b=43.8481(9)Å c=17.0987(3)Å
α=90° β=93.143(2)° γ=90°
(3aS*,5S*,10bS*)-5-(hydroxy(o-tolyl)amino)-10-tosyl-4,5,10,10b-tetrahydropyrrolo[3,4-a]carbazole-1,3(2H,3aH)-dione
C28H25N3O5S,CHCl3
RSC Adv. (2015) 5, 21 16125
a=10.0614(5)Å b=10.2208(5)Å c=15.2649(7)Å
α=104.231(4)° β=95.071(4)° γ=109.240(4)°
(3aS*,5S*,10bS*)-5-((2,6-dibromophenyl)(hydroxy)amino)-N,N-dimethyl-1,3-dioxo-2-phenyl-1,3,3a,4,5,10b-hexahydropyrrolo[3,4-a]carbazole-10(2H)-sulfonamide
C28H24Br2N4O5S,C4H10O
RSC Adv. (2015) 5, 21 16125
a=10.0627(11)Å b=12.5064(17)Å c=13.7858(16)Å
α=87.321(10)° β=78.605(10)° γ=70.030(11)°